Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compassionate Use of Domperidone for Gastrointestinal Disorders
NCT01696734Phase 3Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2012
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of domperidone in gastrointestinal motility disorder, gastroparesis, gastroesophageal reflux disease (GERD), dyspepsia, sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2012; status: active, not recruiting.
02
Drugs
domperidone
03
Conditions
gastrointestinal motility disordergastroparesisgastroesophageal reflux disease (GERD)dyspepsia
Beyond the preview
Go deeper on NCT01696734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01696734.